This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Benefits of technology
[0042]The compounds represented by the formula (1) or the pharmacologically acceptable salts thereof (also referred to as the present compound(s)) exhibit strong inhibitory effects on p
Problems solved by technology
Therefore, many antitumor agents act on not only on cancer cells, but also on normal cells, and consequently any types of side effects develop.
However, with regard to molecular targeting agents, although previous side effects are reduced, there are problems that new side effects are exhibited and alternatives of pharmaceutical agents are limited.
Although the aforementioned antitumor agents were clinically used for the
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0205]To a solution of 3,6-dimethoxy-2-nitrobenzaldehyde (70.0 g) in DMF (420 mL) was added dropwise methyl mercaptoacetate (33.4 mL) at room temperature. Subsequently, potassium carbonate (137 g) was added thereto in 10 parts, and then at unchanged constant temperature the reaction mixture was stirred for 1 hour. Methyl iodide (41.3 mL) was added dropwise thereto, followed by stirring for another 1 hour. The insoluble substance was removed through Celite, and then solvent was evaporated off. The resulting residue was dissolved in ethyl acetate (700 mL), washed with water (2×700 mL) and saturated brine (700 mL), and then dried over sodium sulfate. The solvent was then evaporated off to yield a standard compound as a flesh-colored powder (81.1 g).
[0208]To a solution of methyl 4,7-dimethoxy-1-benzothiophene-2-carboxylate (2.04 g) (which was obtained in Reference example 1) in acetic acid (102 mL) was added dropwise 70% aqueous nitric acid solution (512 μL), and then the reaction mixture was stirred at 70° C. for 1 hour. After it was returned to room temperature, the reaction solution was poured into iced water, and then extracted with chloroform two times. The resulting organic layer was washed with saturated brine, and then dried over sodium sulfate. The solvent was then evaporated off to yield a mixture of 1A and 1B (2.57 g). This was used in the next reaction without further purification.
[0209]To a suspension of 90% reduced iron (2.68 g) and ammonium chloride (555 mg) in methanol / water (57.6 mL / 28.8 mL), which had been heated and stirred at 75° C., was added dropwise a suspension of the obtained mixture of 1A and 1B (2.57 g) in methanol (8.65 mL), and th...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N—R6; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; R1 and R2 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; and R6 is a hydrogen atom or an optionally-substituted C1-6 alkyl group, etc.].
Description
TECHNICAL FIELD[0001]The present invention relates to novel tricyclic quinone derivatives useful as medicament or a pharmacologically acceptable salt thereof. More particularly, the invention relates to pharmaceutical compositions comprising a novel tricyclic quinone derivative or a pharmacologically acceptable salt thereof. The invention relates to therapeutic agents comprising a novel tricyclic quinone derivative comprising the compound, or a pharmacologically acceptable salt thereof.BACKGROUND ART[0002]Cancer develops when abnormality in gene occurs by an action of radiation, ultra violet rays, carcinogen, virus, or the like. The number of deaths by cancer increases year by year, and cancer is currently the top cause of death in Japan. As means for such cancer therapy, antitumor agents, surgical operation, radiotherapy, immunotherapy, and the like are performed. However, among these, the therapeutic use of an antitumor agent is the most important as an internally therapeutic mean...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more